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Abstract The cellular reaction to the DNA-damaging
agents may modulate individual’s cancer susceptibility.
This reaction is mainly determined by the efficacy of DNA
repair, which in turn, may be influenced by the variability
of DNA repair genes, expressed by their polymorphism.
The hOGG1 gene encodes a glycosylase of base excision
repair and RAD51 specifies a key protein in homologues
recombination repair. Both proteins can be involved in the
repair of DNA lesions, which are known to contribute to
endometrial cancer. In the present work we determined
the extent of basal DNA damage and the efficacy of
removal of DNA damage induced by hydrogen peroxide
and N-methyl-N0-nitro N-nitrosoguanidyne (MNNG) in
peripheral blood lymphocytes of 30 endometrial cancer
patients and 30 individuals without cancer. The results
from DNA damage and repair study were correlated with
the genotypes of two common polymorphisms of the
hOGG1 and RAD51 genes: a G[C transversion at 1245
position of the hOGG1 gene producing a Ser ? Cys sub-
stitution at the codon 326 (the Ser326Cys polymorphism)
and a G[C substitution at 135 position of the RAD51 gene
(the 135G[C polymorphism). DNA damage and repair
were evaluated by alkaline single cell gel electrophoresis
and genotypes were determined by restriction fragment
length polymorphism PCR. We observed a strong associ-
ation between endometrial cancer and the C/C genotype of
the 135G[C polymorphism of the RAD51 gene. Moreover,
there was a strong correlation between that genotype and
endometrial cancer occurrence in subjects with a high level
of basal DNA damage. We did not observe any correlation
between the Ser326Cys polymorphism of the hOGG1 gene
and endometrial cancer. Our result suggest that the
135G[C polymorphism of the RAD51 gene may be linked
to endometrial cancer and can be considered as an addi-
tional marker of this disease.
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Introduction
Endometrial cells are constantly under the oxidative stress
during menstrual cycles [1]. The stress is generated in the
metabolic reactions of estrogens, producing reactive oxy-
gen species (ROS), which can cause damages to biomole-
cules, including DNA [2]. ROS may induce mutations in
proto-oncogenes and tumor suppressor genes, as well as in
other genes important for induction, promotion and pro-
gression of cancer, accelerating up malignant transforma-
tion [3, 4]. Oxidative damages to the DNA bases are
mainly removed by base excision repair (BER) pathway.
hOGG1 is a key BER enzyme to recognize and excise of
8-hydroxy-deoxyguanine (8-oxo-dG), which cause G[A
transversion [5–8].
hOGG1, the gene encoding hOGG1, is highly poly-
morphic [9]. A C[G transversion at the 1245 position in
the exon 7 of the gene results in a serine to cysteine
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substitution in the codon 326 (the Ser326Cys polymor-
phism; rs 1052133). The role of this polymorphism in the
catalytic activity of the hOGG1 protein is still controver-
sial. Several studies have suggested that Cys326 allele may
be associated with the increased risk cancers [10–21]. For
prostate cancer it was shown that Cys326Cys variant of
hOGG1 reduced cancer risk of more aggressive disease
[22].
Hydroxyl radicals can attack sugar-phosphate backbone
of DNA, producing single strand breaks, which could be
converted into double strand breaks (DSBs) in replication
or generation of another single strand break on the opposite
DNA strand. RAD51-depended homologous DNA recom-
bination repair (HRR) is one of major pathways for the
repair of DSBs in human cells. HRR has been implicated in
the resuming of stalled replication fork and RAD51 protein
plays essential role in this process. HRR is also involved in
the repair of DNA-protein cross-links in cooperation with
nucleotide excision repair (NER). Human RAD51 is
required for meiotic and mitotic recombination and plays
a central role in homology-dependent recombinational
repair of DSBs [23, 24]. A single nucleotide polymorphism
in the 50-untranslated region (50-UTR) of the human
RAD51 gene, resulting in a G[C substitution at the 135
position (the 135G[C polymorphism; c. -98 G[C; rs
1801320), has been identified [25]. We showed previously
that this polymorphism was not an independent marker in
breast cancer, but it could be associated with an increased
gastric cancer risk and an increased breast cancer risk in
BRCA2 mutation carriers [26, 27]. Similar results came
from other laboratories [25, 28].
In the present work we tried to correlate the genetic
constitution expressed by genotypes of the Ser326Cys and
135G[C polymorphisms of the hOGG1 and RAD51 genes,
respectively, with susceptibility to DNA damage and effi-
cacy of DNA repair in human lymphocytes of endometrial
cancer patients. To evaluate the extent of DNA damage, the
effectiveness of DNA repair and the sensitivity to exoge-
nous mutagens we determined: (1) the level of basal DNA
damage and (2) the capacity to remove DNA damage
induced by hydrogen peroxide and N-methyl-N0-nitro
N-nitrosoguanidyne (MNNG) in peripheral blood lym-
phocytes of endometrial cancer patients and healthy indi-
viduals. DNA damage and repair were evaluated by
alkaline single cell gel electrophoresis (comet assay).
Materials and methods
Patients
Blood samples were obtained from 30 patients with his-
tologically confirmed endometrial cancer (median age
55 years) treated at the Department of Oncological
Surgery, N. Copernicus Hospital (Lodz, Poland) and Polish
Mother’s Memorial Hospital (Lodz, Poland) in 2006 and
2007 and 30 cancer-free age-matched women. Blood from
patients was collected before surgical treatment and
radiotherapy. The study was approved by the Local Ethic
Committee and each patient gave a written consent.
Cell preparation
Blood samples were immediately transported to the labo-
ratory on ice. Peripheral blood lymphocytes (PBL) were
isolated by centrifugation in a density gradient of
Histopaque-1077 (15 min, 280 9 g). The pellet containing
PBL was resuspended in RPMI 1640 medium to give about
(1–3) 9 105 cells per ml and further processed.
Comet assay
The comet assay was performed under alkaline conditions
essentially according to the procedure of Singh et al. [29]
with some modifications as described previously [30].
Peripheral blood lymphocytes were incubated with
hydrogen peroxide (10 mM for 10 min at 0C) and MNNG
(200 nM for 1 h at 37C) to evaluate the efficacy of DNA
repair. After incubation, cells were washed and incubated in
a fresh, drug-free medium for 2 h at 37C. The comets were
observed at 9200 magnification in an Eclipse fluorescence
microscope (Nikon, Tokyo, Japan) attached to a COHU
4910 video camera (Cohu, San Diego, CA, USA) equipped
with UV-1 filter block (an excitation filter of 359 nm and a
barrier filter of 461 nm) and connected to a personal com-
puter-based Lucia-Comet v. 4.51 image analysis system
(Laboratory Imaging, Prague, Czech Republic). The mean
of percentage of DNA in the tail of comet for a total of 100
cells was calculated. All the values in this study were
expressed as mean ± SE.
Genotype determination
Genomic DNA was prepared by the standard phenol pro-
cedure as we described previously [31]. RAD51 genotyping
was analyzed by a PCR amplification of a 157-bp region
around the 135th nucleotide. This region contains a single
MvaI site that was abolished in the 135C variant. Wild
type alleles were digested by MvaI (Fermentas, Vilnius,
Lithuania) producing 86 and 71 bp length products. The
135C variant of RAD51 was not digested by the enzyme,
giving a single 157 bp PCR product. PCR was performed
in a MT Research, INC thermal cycler with the following
primers: sense: 50-TGGGAACTGCAACTCATCTGG-30
and 50-GCGCTCCTCTCTCCAGCAG-30 at a final Mg2?
concentration of 1.5 mM and annealing temperature of
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53C. After overnight digestion with the enzyme, the
samples were separated onto a 8% polyacrylamide gel. The
genotypes of the other polymorphism were determined
with the following primers: sense 50-GTTTTCACTAAT
GAGCTTGC-30, antisense 50-AGTGGTATAATCATGT
GGGT-30 at a final Mg2? concentration of 1.5 mM and
annealing temperature of 57C. The 200 bp PCR product
was digested overnight with 5 U of the restriction enzyme
SatI (Fermentas, Vilnius, Lithuania). The Cys allele was
digested into 100 bp fragments whereas the Ser variant
remained intact. The PCR products were run on a 8% of
polyacrylamide gel [12, 26, 27].
Data analysis
Distribution of genotypes and alleles between groups were
analyzed using the v2-test. Relationship between genotype
and cancer was assessed by the unconditional logistic
regression (quasi-Newton method). For each SNP, odds
ratio (OR) was estimated. Wild type alleles or addi-
tional homozygous variants were used as reference groups.
Efficacy of DNA repair was analyzed using Wilcoxon
matched pair test. Analyses were performed using STAT-
ISTICA 8.0 package (Statsoft, Tulusa, OK, USA) and
P \ 0.05 was considered statistically significant.
Results
DNA damage
The mean extent of endogenous DNA damage measured as
the percentage of DNA in comet tail of the lymphocytes of
endometrial cancer patients and controls is displayed in
Fig. 1. There were no differences between the extents of
DNA damage for both groups (P [ 0.05).
Sensitivity to DNA-damaging agents and efficacy
of DNA repair
The mean percentage tail DNA of PBL from endometrial
cancer patients and controls exposed to 10 mM hydrogen
peroxide or 200 nM MNNG immediately after the exposure
as well as 120 min thereafter are presented in Tables 1 and
2. We do not observed any differences in the mean sensi-
tivity to hydrogen peroxide and MNNG (the mean extent of
DNA damage immediately after exposure) for patients and
controls. We observed a great variation in the individual
efficacy of DNA repair. Both patients and controls had
comparable number of subjects with inefficient DNA
repair, in other words, with not any statistically significant
difference between the level of DNA damage at 120 and
0 min (bolded).
Genotype analysis
Tables 3 and 4 show the distribution of genotypes of the
Ser326Cys and 135G[C polymorphism for cancer patients
and controls. A strong association of the C/C genotype (OR
25.3, 95% CI 4.48–143) and the C allele (OR 7.23, 95% CI
3.20–16.35) and endometrial cancer occurrence was
observed. Table 5 shows the distribution of genotypes of
the 135G[C polymorphism in patients and controls with
high, i.e. higher than median, level of endogenous DNA
damage. There was a strong association between endo-
metrial cancer occurrence and the C/C genotype (OR 13.2,
95% CI 1.47–123) and the C allele (OR 4.75, 95% CI 1.58–
14.3) in patients with elevated level of basal DNA lesions.
There were no significant differences between the distri-
butions of the other polymorphism in cancer patients and
controls with high level of endogenous DNA damage
(Table 6). No correlation was found between both poly-
morphism and endometrial cancer occurrence in subjects
with impaired DNA repair after hydrogen peroxide and
MNNG treatment (data not shown).
Discussion
In our study we did not observe any difference between
basal endogenous level of DNA damage in lymphocytes of
endometrial cancer patients and non-cancer controls. The
same concerns the susceptibility of lymphocytes to DNA-
damaging agent in these two groups. On the other hand, it
was shown that a long-term estrogens exposure was asso-
ciated with endometrial and ovarian cancer risk [32].
Fig. 1 Endogenous DNA damage (DNA strand breaks and alkali
labile sites), measured as the mean percentage of comet tail DNA in
the alkaline comet assay in human peripheral blood lymphocytes of
healthy controls and endometrial cancer patients. Thirty individuals
were analyzed in either group. The results displayed are the
mean ± SE
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Estrogen metabolites can cause DNA damage in many
tissues [33, 34]. Primarily they form unstable N-3 adenine
and N-7 guanine adducts resulting in mutagenic apurinic
sites, witch are easily detected by comet assay. The alka-
line single cell-gel electrophoresis was used to examine
oestrogens (beta-estradiol, estrone and estriol) activities on
the estrogen-responsive MCF-7 human breast cancer cells
for chromosomal damage and DNA single-strand breaks
(SSBs). Both beta-estradiol and estrone induced dose-
related increases in SSBs (up to sevenfold over control) at
concentrations as low as 10-9 and 10-8 M, while estriol
was less genotoxic [35]. In the present study we showed
that genotoxic effect of estrogens cannot be observed in
non estrogen-responsive target cells, such as lymphocytes.
We showed that there are no significant differences in
basal endogenous DNA damage in lymphocytes from
patients with endometrial cancer and healthy controls. It is
in agreement with other studies performed on human
lymphocytes [36–38].
Our results obtained for the 135G[C polymorphism of
the RAD51 gene indicated that both the C/C genotype
and the C allele are strongly associated with endometrial
cancer. The 135G[C polymorphism of the RAD51 gene was
reported to change breast cancer risk in BRCA2 mutations
carriers [25, 26, 28]. It is located in the 50-untranslated
region of the RAD51 gene, so it could affect the gene
expression and, as a consequence, alter the concentration of
the final product—the RAD51 protein. RAD51 takes a part
Table 1 Repair of hydrogen peroxide-induced DNA damage in 30 endometrial cancer patients and 30 healthy controls
Endometrial cancer DNA damage ± SE Control DNA damage ± SE
Number 0 min 120 min P Number 0 min 120 min P
1 16.5 ± 5.55 5.33 ± 0.79 \0.05 1 17.3 ± 0.66 7.52 ± 0.91 \0.05
2 9.44 ± 3.05 3.23 ± 0.44 \0.05 2 15.7 ± 3.20 2.61 ± 0.81 \0.05
3 8.43 ± 2.46 0.87 ± 1.12 \0.05 3 9.59 ± 1.88 1.57 ± 0.87 \0.05
4 12.5 ± 3.32 6.04 ± 1.61 \0.05 4 19.8 ± 0.58 9.76 ± 2.03 \0.05
5 7.99 ± 2.70 4.95 ± 1.17 \0.05 5 14.8 ± 0.11 10.3 ± 0.52 \0.05
6 7.68 ± 1.61 4.48 ± 2.12 \0.05 6 58.1 ± 3.39 12.3 ± 3.02 \0.05
7 22.6 ± 1.44 23.9 ± 1.72 0.2567 7 46.7 ± 3.36 6.49 ± 0.63 \0.05
8 59.0 ± 12.74 48.3 ± 5.46 0.2972 8 29.9 ± 1.48 26.6 ± 2.12 0.2972
9 14.5 ± 1.17 7.06 ± 1.98 \0.05 9 20.5 ± 2.00 10.8 ± 0.62 \0.05
10 18.6 ± 3.15 11.3 ± 1.48 \0.05 10 76.5 ± 3.61 8.77 ± 2.40 \0.05
11 16.4 ± 2.58 8.43 ± 0.84 \0.05 11 22.9 ± 0.59 24.0 ± 2.03 0.4314
12 25.3 ± 2.26 8.13 ± 1.75 \0.05 12 22.6 ± 2.24 3.92 ± 0.38 \0.05
13 25.7 ± 1.08 6.06 ± 2.46 \0.05 13 18.2 ± 1.48 1.61 ± 0.45 \0.05
14 67.5 ± 2.87 59.6 ± 2.55 0.2894 14 8.33 ± 0.98 3.77 ± 1.72 \0.05
15 39.0 ± 2.45 25.0 ± 2.81 \0.05 15 29.0 ± 2.32 1.17 ± 0.63 \0.05
16 28.9 ± 2.39 19.0 ± 1.20 \0.05 16 10.4 ± 1.52 9.19 ± 1.73 0.2540
17 47.3 ± 5.33 35.1 ± 2.78 \0.05 17 9.8 ± 5.09 6.84 ± 1.72 \0.05
18 26.6 ± 3.01 7.41 ± 0.84 \0.05 18 28.3 ± 3.61 22.7 ± 3.96 0.4486
19 14.5 ± 3.27 11.8 ± 4.03 0.0814 19 22.2 ± 1.94 14.5 ± 1.52 \0.05
20 12.0 ± 2.03 13.8 ± 2.01 0.0978 20 27.8 ± 1.29 13.7 ± 1.85 \0.05
21 19.1 ± 3.64 6.23 ± 1.36 \0.05 21 25.0 ± 3.14 12.6 ± 2.16 \0.05
22 21.7 ± 3.64 3.66 ± 2.11 \0.05 22 28.5 ± 3.98 2.87 ± 2.85 \0.05
23 13.5 ± 3.26 7.94 ± 2.28 \0.05 23 18.0 ± 1.11 3.35 ± 0.86 \0.05
24 17.3 ± 1.14 7.52 ± 1.19 \0.05 24 18.8 ± 2.22 11.3 ± 3.09 \0.05
25 11.4 ± 1.06 11.4 ± 1.48 0.8281 25 7.19 ± 1.61 7.69 ± 1.80 0.1080
26 15.7 ± 1.12 3.77 ± 1.35 \0.05 26 58.9 ± 3.07 8.78 ± 1.03 \0.05
27 24.5 ± 2.67 11.9 ± 2.38 \0.05 27 10.7 ± 1.94 10.5 ± 1.14 0.2994
28 23.8 ± 1.88 8.22 ± 1.51 \0.05 28 24.5 ± 2.07 27.3 ± 1.48 0.2103
29 10.7 ± 1.44 10.5 ± 1.01 0.0767 29 11.2 ± 1.17 8.05 ± 0.77 \0.05
30 22.1 ± 1.69 6.75 ± 1.64 \0.05 30 11.9 ± 1.22 5.89 ± 0.88 \0.05
DNA damage for each treatment was analyzed as the percentage of DNA in the tail of 100 comets; mean ± SE. The efficacy of DNA repair was
calculated by comparing the extent of DNA damage immediately and 120 min after hydrogen peroxide treatment using Wilcoxon matched pairs
test. The subjects with no significant repair (P [ 0.05) are presented bold
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in the repair of DNA double strand breaks (DSBs), the most
dangerous damage to DNA. The formation of RAD51 foci
represents an important step in the repair of DNA double-
strand breaks. RAD51 foci also appear during S phase and
are thought to be required for the restart of stalled or broken
replication fork. The RAD51 recombinase interacts directly
with the breast cancer-associated tumor suppressor BRCA2
and this interaction is required for normal recombination
proficiency, radiation resistance and genome stability
[39–46]. There are no epidemiological studies linked the
135G[C polymorphism with endometrial cancer. Studies in
mice suggested a role of polymorphic variants of RAD51 in
radiation induced acute myeloid leukemia [47].
Antoniou et al. suggests an effect of the RAD51 135C
homozygotes on the RAD51 alternative splicing within the
50 UTR. Isoform for 135C genotype has lower translation
efficiency and may cause an overall lower abundance of
RAD51 protein [48].
Our present data confirm our previous suggestion that
the 135G[C polymorphism of the RAD51 gene have a
phenotypic effect, manifested in the changes in the extent
of DNA damage [12].
Human tumors often display loss of heterozygosity at the
hOGG1 locus. Bacterial and yeast cells deficient in the repair
of 8-oxoG repair display a hypermutator phenotype [49, 50].
Mice deficient for ogg1 accumulate abnormal levels of
Table 2 Repair of MNNG-induced DNA damage in 30 endometrial cancer patients and 30 healthy controls
Endometrial cancer DNA damage ± SE Control DNA damage ± SE
Number 0 min 120 min P Number 0 min 120 min P
1 24.2 ± 3.09 13.3 ± 0.56 \0.05 1 15.2 ± 2.82 5.35 ± 0.30 \0.05
2 10.2 ± 0.68 3.93 ± 1.16 \0.05 2 15.4 ± 0.67 3.99 ± 0.62 \0.05
3 5.94 ± 1.83 2.41 ± 0.25 \0.05 3 17.0 ± 1.94 6.16 ± 0.50 \0.05
4 9.94 ± 0.75 5.55 ± 2.32 0.069 4 12.7 ± 1.54 7.36 ± 1.80 \0.05
5 16.8 ± 1.42 2.61 ± 0.34 \0.05 5 14.9 ± 0.73 5.22 ± 2.12 \0.05
6 5.46 ± 0.71 3.02 ± 1.20 \0.05 6 46.3 ± 2.02 21.7 ± 1.08 \0.05
7 36.8 ± 3.7 11.4 ± 0.86 \0.05 7 31.3 ± 0.57 13.5 ± 1.27 \0.05
8 37.4 ± 2.25 37.0 ± 0.58 0.760 8 36.5 ± 2.15 36.0 ± 1.54 0.942
9 15.3 ± 2.00 7.56 ± 0.46 \0.05 9 21.3 ± 1.09 28.1 ± 3.95 –
10 9.85 ± 0.73 5.25 ± 0.55 \0.05 10 95.9 ± 1.74 14.5 ± 0.82 \0.05
11 9.44 ± 1.40 7.57 ± 2.43 0.083 11 26.3 ± 1.72 25.6 ± 2.03 0.853
12 21.3 ± 2.25 8.56 ± 0.63 \0.05 12 36.8 ± 3.81 11.4 ± 0.89 \0.05
13 27.5 ± 0.31 8.81 ± 0.39 \0.05 13 10.6 ± 0.67 6.51 ± 1.22 \0.05
14 70.0 ± 0.74 54.5 ± 2.90 0.058 14 10.5 ± 0.79 3.69 ± 0.98 \0.05
15 17.0 ± 0.47 9.54 ± 0.30 \0.05 15 13.7 ± 1.19 1.41 ± 0.14 \0.05
16 20.7 ± 0.39 25.8 ± 2.26 0.067 16 5.68 ± 3.95 5.53 ± 1.75 0.546
17 45.2 ± 0.29 21.5 ± 0.28 \0.05 17 6.52 ± 0.84 2.23 ± 3.74 \0.05
18 39.0 ± 0.51 7.27 ± 0.21 \0.05 18 12.5 ± 2.03 14.4 ± 1.31 0.070
19 10.5 ± 1.65 9.44 ± 1.35 0.453 19 33.2 ± 0.78 14.6 ± 0.60 \0.05
20 10.5 ± 2.89 14.1 ± 2.04 0.098 20 24.3 ± 1.75 15.9 ± 1.53 \0.05
21 9.14 ± 2.01 4.23 ± 0.84 \0.05 21 32.5 ± 1.33 16.1 ± 0.99 \0.05
22 13.3 ± 1.27 4.77 ± 0.83 \0.05 22 16.9 ± 1.10 6.69 ± 1.34 \0.05
23 8.30 ± 3.23 2.77 ± 0.59 \0.05 23 14.9 ± 2.19 12.8 ± 0.86 0.084
24 15.2 ± 2.42 5.35 ± 0.45 \0.05 24 19.9 ± 0.40 2.64 ± 1.97 \0.05
25 9.09 ± 1.36 4.26 ± 0.84 \0.05 25 7.64 ± 0.66 3.2 ± 2.07 \0.05
26 15.7 ± 0.66 3.99 ± 0.66 \0.05 26 52.7 ± 1.95 11.4 ± 2.23 \0.05
27 15.5 ± 2.28 5.79 ± 1.09 \0.05 27 7.64 ± 0.46 3.20 ± 0.07 \0.05
28 29.4 ± 1.22 19.9 ± 2.58 \0.05 28 15.5 ± 3.81 14.0 ± 2.35 0.750
29 17.2 ± 0.73 11.7 ± 1.74 \0.05 29 12.3 ± 0.64 6.06 ± 0.52 \0.05
30 11.0 ± 0.35 6.56 ± 0.45 \0.05 30 11.9 ± 0.92 4.48 ± 0.53 \0.05
‘‘–’’ Not estimated
DNA damage for each treatment was analyzed as the percentage of DNA in the tail of 100 comets; mean ± SE. The efficacy of DNA repair was
calculated by comparing the extent of DNA damage immediately and 120 min after MNNG treatment using Wilcoxon matched pairs test. The
subjects with no significant repair (P [ 0.05) are presented bold
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8-oxoG and have an elevated spontaneous mutation rate
[51]. It was suggested that hOGG1–Cys326 enzyme had a
lover ability to suppress mutation than wild type Ser326
protein in human cells in vitro [52]. Even though no dif-
ferences in catalytic activity was shown among Ser326 and
Cys326 variants in one study [36], the other shows that
Ser326Cys and Cys326Cys genotypes displayed slower
DNA repair than the Ser326Ser genotype [53] and the
hOGG1 protein encoded by the Ser326 allele had signifi-
cantly higher activity than the Cys326 variants in an in vitro
complementation activities assay [6]. Interestingly, this
effect is not related to difference in the expression rate of
polymorphic variants. The hOGG1 Cys326Cys genotype
had significantly higher expression level of the hOGG1
mRNA than Ser326Ser genotype [54, 55]. Replacement of
wild type serine at residue 326 (allele frequencies of 0.55–
0.67 in Asians and 0.73–0.78 in the Caucasians populations)
with redox sensitive cysteine resulted in attenuated activity
under oxidative stress. It is also possible that loss of phos-
phorylation site on Ser326 provide to aberrant nuclear
localization of the Cys variant of the enzyme [56, 57].
In summary, our results suggest that the variants of the
135G[C polymorphism of the RAD51 gene can be asso-
ciated with the occurrence of endometrial cancer in indi-
viduals with a high level of DNA damage. Therefore, this
polymorphism can be considered as an additional marker in
endometrial cancer.
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